0
0
Home » Medical Devices » Dental Devices

Tissue Regenerative Materials Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update

Tissue Regenerative Material is a biomaterial component which facilitates regeneration of lost periodontal hard and soft tissue. One unit refers to one ml of tissue regenerative material.

Tissue Regenerative Materials Pipeline market research report including provides comprehensive information about the Tissue Regenerative Materials pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Which are the key territories in the tissue regenerative materials pipeline market?

The key territories in the tissue regenerative materials pipeline market are the United States, Europe, Japan, New Zealand, Taiwan, and Australia. The United States has the highest number of pipeline products.

Tissue regenerative materials pipeline market, by territories

Tissue regenerative materials pipeline market, by territories

For more territory insights, download a free report sample

Which are the key regulatory paths in the tissue regenerative materials pipeline market?

The key regulatory paths in the tissue regenerative materials pipeline market are 510(k), CE, Ninsho, TGA, and BOPA. 510(k) has the highest number of pipeline products.

Tissue regenerative materials pipeline market, by regulatory paths

Tissue regenerative materials pipeline market, by regulatory paths

For more regulatory path insights, download a free report sample

Which are the key companies in the tissue regenerative materials pipeline market?

The key companies in the tissue regenerative materials pipeline market are Advanced Biotech Products Pvt Ltd, Colorado Therapeutics, LLC, credentis AG, Histocell SL, Indian Institute of Technology Bombay, Maxigen Biotech Inc, and Medtronic Plc.

Market report overview

Key territories United States, Europe, Japan, New Zealand, Taiwan, and Australia
Key regulatory paths 510(k), CE, Ninsho, TGA, and BOPA
Key companies Advanced Biotech Products Pvt Ltd, Colorado Therapeutics, LLC, credentis AG, Histocell SL, Indian Institute of Technology Bombay, Maxigen Biotech Inc, and Medtronic Plc

Scope

  • Extensive coverage of the Tissue Regenerative Materials under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Tissue Regenerative Materials and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy

The report enables you to:

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Tissue Regenerative Materials under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Key Players

Advanced Biotech Products Pvt Ltd

Colorado Therapeutics, LLC

credentis AG

Histocell SL

Indian Institute of Technology Bombay

Maxigen Biotech Inc

Medtronic Plc

Nobel Biocare Services AG

Novatissue SAS

Orthocell Ltd

Orthorebirth Co Ltd

Polytechnic University of Catalonia

Straumann Holding AG

SurgaColl Technologies Ltd

SweetBio, Inc.

Tetratherix Pty Ltd

Tigran Technologies AB

Table of Contents

1 Table of Contents 3

|1.1 List of Tables 5

|1.2 List of Figures 7

2 Introduction 8

2.1 Tissue Regenerative Materials Overview 8

3 Products under Development 9

3.1 Tissue Regenerative Materials – Pipeline Products by Stage of Development 9

3.2 Tissue Regenerative Materials – Pipeline Products by Territory 10

3.3 Tissue Regenerative Materials – Pipeline Products by Regulatory Path 11

3.4 Tissue Regenerative Materials – Pipeline Products by Estimated Approval Date 12

3.5 Tissue Regenerative Materials – Ongoing Clinical Trials 13

4 Tissue Regenerative Materials – Pipeline Products under Development by Companies 14

4.1 Tissue Regenerative Materials Companies – Pipeline Products by Stage of Development 14

4.2 Tissue Regenerative Materials – Pipeline Products by Stage of Development 15

5 Tissue Regenerative Materials Companies and Product Overview 16

5.1 Advanced Biotech Products Pvt Ltd Company Overview 16

5.1.1 Advanced Biotech Products Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 16

5.2 Colorado Therapeutics, LLC Company Overview 19

5.2.1 Colorado Therapeutics, LLC Pipeline Products & Ongoing Clinical Trials Overview 19

5.3 credentis AG Company Overview 20

5.3.1 credentis AG Pipeline Products & Ongoing Clinical Trials Overview 20

5.4 Histocell SL Company Overview 21

5.4.1 Histocell SL Pipeline Products & Ongoing Clinical Trials Overview 21

5.5 Indian Institute of Technology Bombay Company Overview 22

5.5.1 Indian Institute of Technology Bombay Pipeline Products & Ongoing Clinical Trials Overview 22

5.6 Maxigen Biotech Inc Company Overview 23

5.6.1 Maxigen Biotech Inc Pipeline Products & Ongoing Clinical Trials Overview 23

5.7 Medtronic Plc Company Overview 24

5.7.1 Medtronic Plc Pipeline Products & Ongoing Clinical Trials Overview 24

5.8 Nobel Biocare Services AG Company Overview 25

5.8.1 Nobel Biocare Services AG Pipeline Products & Ongoing Clinical Trials Overview 25

5.9 Novatissue SAS Company Overview 26

5.9.1 Novatissue SAS Pipeline Products & Ongoing Clinical Trials Overview 26

5.10 Orthocell Ltd Company Overview 27

5.10.1 Orthocell Ltd Pipeline Products & Ongoing Clinical Trials Overview 27

5.11 Orthorebirth Co Ltd Company Overview 28

5.11.1 Orthorebirth Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 28

5.12 Polytechnic University of Catalonia Company Overview 29

5.12.1 Polytechnic University of Catalonia Pipeline Products & Ongoing Clinical Trials Overview 29

5.13 Straumann Holding AG Company Overview 30

5.13.1 Straumann Holding AG Pipeline Products & Ongoing Clinical Trials Overview 30

5.14 SurgaColl Technologies Ltd Company Overview 31

5.14.1 SurgaColl Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 31

5.15 SweetBio, Inc. Company Overview 32

5.15.1 SweetBio, Inc. Pipeline Products & Ongoing Clinical Trials Overview 32

5.16 Tetratherix Pty Ltd Company Overview 33

5.16.1 Tetratherix Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 33

5.17 Tigran Technologies AB Company Overview 36

5.17.1 Tigran Technologies AB Pipeline Products & Ongoing Clinical Trials Overview 36

6 Tissue Regenerative Materials- Recent Developments 37

6.1 May 26, 2022: CollPlant Biotechnologies Provides Business Updates and First Quarter 2022 Financial Results 37

6.2 Apr 13, 2022: CollPlant To Present at the Aesthetics Innovation Summit 2022 38

6.3 Mar 24, 2022: CollPlant Biotechnologies Provides Business Updates and Fiscal Year 2021 Financial Results 39

6.4 Feb 15, 2022: Straumann Group reports revenue exceeding CHF 2 billion 40

6.5 Feb 04, 2022: Straumann Group announces invitation for 2021 full-year financial results webcast 42

6.6 Jan 25, 2022: Medprin Regenerative Medical Technologies Announces on the resignation of the company’s director and board secretary 43

6.7 Jan 07, 2022: Collagen Matrix Names Tony Orsini Chief Operating Officer 43

6.8 Dec 21, 2021: Maipu Medical Announcement on Appointment of Deputy General Manager of the Company 43

6.9 Nov 18, 2021: CollPlant Biotechnologies Provides Business Updates and Third Quarter 2021 Financial Results 44

6.10 Oct 18, 2021: Straumann Group 2021 third-quarter financial results webcast invitation 46

6.11 Aug 19, 2021: CollPlant Biotechnologies Provides Business Updates and Second Quarter 2021 Financial Results 46

6.12 Jul 29, 2021: Invitation: Straumann Group 2021 half-year financial results webcast 48

6.13 Jul 15, 2021: Christian Ullrich joins Straumann Group’s Executive Management Board as the new Group Chief Information Officer 48

7 Appendix 50

7.1 Methodology 50

7.2 About GlobalData 52

7.3 Contact Us 53

7.4 Disclaimer 53

List of Tables

Tissue Regenerative Materials – Pipeline Products by Stage of Development 9

Tissue Regenerative Materials – Pipeline Products by Territory 10

Tissue Regenerative Materials – Pipeline Products by Regulatory Path 11

Tissue Regenerative Materials – Pipeline Products by Estimated Approval Date 12

Tissue Regenerative Materials – Ongoing Clinical Trials 13

Tissue Regenerative Materials Companies – Pipeline Products by Stage of Development 14

Tissue Regenerative Materials – Pipeline Products by Stage of Development 15

Advanced Biotech Products Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 16

Healiguide – Product Status 16

Healiguide – Product Description 16

Osseograft – Product Status 17

Osseograft – Product Description 17

Osseomold – Product Status 17

Osseomold – Product Description 18

Colorado Therapeutics, LLC Pipeline Products & Ongoing Clinical Trials Overview 19

Xenograft Implant – Dental – Product Status 19

Xenograft Implant – Dental – Product Description 19

credentis AG Pipeline Products & Ongoing Clinical Trials Overview 20

CUROLOX Perio – Product Status 20

CUROLOX Perio – Product Description 20

Histocell SL Pipeline Products & Ongoing Clinical Trials Overview 21

HR018-Neofibrin – Product Status 21

HR018-Neofibrin – Product Description 21

Indian Institute of Technology Bombay Pipeline Products & Ongoing Clinical Trials Overview 22

Electrospun Scaffold – Product Status 22

Electrospun Scaffold – Product Description 22

Maxigen Biotech Inc Pipeline Products & Ongoing Clinical Trials Overview 23

MaxiGuide – Product Status 23

MaxiGuide – Product Description 23

Medtronic Plc Pipeline Products & Ongoing Clinical Trials Overview 24

MD08 – Product Status 24

MD08 – Product Description 24

Nobel Biocare Services AG Pipeline Products & Ongoing Clinical Trials Overview 25

Bone Inductive Implant – Product Status 25

Bone Inductive Implant – Product Description 25

Novatissue SAS Pipeline Products & Ongoing Clinical Trials Overview 26

OrthoNovaOss – Product Status 26

OrthoNovaOss – Product Description 26

Orthocell Ltd Pipeline Products & Ongoing Clinical Trials Overview 27

Striate+ – Product Status 27

Striate+ – Product Description 27

Orthorebirth Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 28

GCT-101 – Product Status 28

GCT-101 – Product Description 28

Polytechnic University of Catalonia Pipeline Products & Ongoing Clinical Trials Overview 29

Inorganic Dental Cement – Product Status 29

Inorganic Dental Cement – Product Description 29

Straumann Holding AG Pipeline Products & Ongoing Clinical Trials Overview 30

Soft Tissue Control Implant – Product Status 30

Soft Tissue Control Implant – Product Description 30

SurgaColl Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 31

DentaColl – Product Status 31

DentaColl – Product Description 31

SweetBio, Inc. Pipeline Products & Ongoing Clinical Trials Overview 32

SweetBio GTR (Guided Tissue Regeneration) Membrane – Product Status 32

SweetBio GTR (Guided Tissue Regeneration) Membrane – Product Description 32

Tetratherix Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 33

Tetramax – Product Status 33

Tetramax – Product Description 33

Tetratherix Pty Ltd – Ongoing Clinical Trials Overview 34

Tetramax – PET-B: Post Extraction Use of TetraMax Part B (TMB).. A Comparator Controlled Clinical Investigation Comparing the Bone Healing Capability of the Investigational Product “TetraMax Plus BioOss” and the Gold Standard Standard of Care Comparator “BioOssCollagen” (BioOssCol), for Adults Who Have Been Treatment Planned for Tooth Extraction/s and Implant Placement at the Same Extraction Site/s 35

Tigran Technologies AB Pipeline Products & Ongoing Clinical Trials Overview 36

Tigran Porous Titanium Granules – Alveolar Fillings – Product Status 36

Tigran Porous Titanium Granules – Alveolar Fillings – Product Description 36

Glossary 52

List of Figures

Tissue Regenerative Materials – Pipeline Products by Stage of Development 9

Tissue Regenerative Materials – Pipeline Products by Territory 10

Tissue Regenerative Materials – Pipeline Products by Regulatory Path 11

Tissue Regenerative Materials – Pipeline Products by Estimated Approval Date 12

Tissue Regenerative Materials – Ongoing Clinical Trials 13

Frequently Asked Questions

The key territories in the tissue regenerative materials pipeline market are the United States, Europe, Japan, New Zealand, Taiwan, and Australia.

 

 

 

The key regulatory paths in the tissue regenerative materials pipeline market are 510(k), CE, Ninsho, TGA, and BOPA.

The key companies in the tissue regenerative materials pipeline market are Advanced Biotech Products Pvt Ltd, Colorado Therapeutics, LLC, credentis AG, Histocell SL, Indian Institute of Technology Bombay, Maxigen Biotech Inc, and Medtronic Plc.

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2960

Join our mailing list

Saved reports